It is administered in 3 doses over a period of 2 months. Efficacy In August 2021, preliminary data from a phase III study with 28,500 participants indicated an overall efficacy of 82% against disease of any severity. Efficacy was 93% against the Alpha variant and 78% against the Delta variant. In July 2021, lab studies showed<unk>  retained neutralizing effects against B.1.429 (Epsilon), B.1.351(Beta), P.1(Gamma), B.1.525(Eta), B.1.617.1(Kappa), the neutralizing titers decreased ranging from 1.1 fold to 2.1 fold, but the neutralizing efficacy were still good.
ZF2001
DEBRA
HAMLET 
ACDC 
CoWIN
MIS416
ESKAPE
ABL 